Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
16
4
4
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.3%
1 terminated out of 16 trials
80.0%
-6.5% vs benchmark
13%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (16)
Non-invasive Vagal Neurostimulation (nVNS) for Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
ALI/ARDS Clinical Sub-phenotyping Study
VExUS in Ards Patients and Association with AKI
Infants with Severe Acute Respiratory Distress Syndrome: the Prone Trial
Evaluation of VQm PHM on Pulmonary Health Parameters for ICU
Rehabilitation for People With COVID-19 in ICU
Mechanism of Delayed Neutrophil Apoptosis in Acute Lung Injury
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
FSTL1 and PPCs on Pediatric Within LDLT:a Prospective Cohort Analysis
Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS
Improvement of Pulmonary Insufficiency After Aortic Dissection With Sivelestat Sodium
Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS
SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19